Regeneron Pharmaceuticals' Pipeline Progress Raises Costs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 29, 5:30PM CDT
Regeneron (REGN) expects adjusted SG&A costs to rise further in the remaining quarters of 2014.
Final Glance: Biotechnology companies
AP - Fri Aug 29, 5:07PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:
Midday Glance: Biotechnology companies
AP - Fri Aug 29, 12:19PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
4 Biotechs That Might Be Bought Soon
at Investor's Business Daily - Fri Aug 29, 10:53AM CDT
The recent announcement that Roche (RHHBY) will buy InterMune (ITMN) for $8.3 billion brought new life to M&A speculation in the biotech industry, which had been relatively neglected as the buzz focused on tax-inversion deals by biopharmaceutical...
Early Glance: Biotechnology companies
AP - Fri Aug 29, 9:31AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Upcoming Conferences Schedule, Clinical Trial Data Release Schedule, Milestone Payment, and Expansion of Partnership - Research Reports on Celgene, Actavis, Regeneron, ISIS and UnitedHealth
PR Newswire - Fri Aug 29, 8:10AM CDT
Today, Analysts Review released its research reports regarding Celgene Corporation (NASDAQ: CELG), Actavis plc (NYSE: ACT), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS) and UnitedHealth Group Inc. (NYSE: UNH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6076-100free.
Bristol-Myers' Oral HCV Treatment Daklinza Gets EU Clearance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 28, 5:50PM CDT
Bristol-Myers' (BMY) Daklinza has been cleared in the EU.
Biotech Stock Roundup: Biotechs Surge on InterMune Acquisition Deal, Focus on More M&As - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Aug 27, 9:32AM CDT
Roche's agreement to acquire InterMune has raised hopes for more such deals in the biotech sector.
Celgene rose 2.4%
at Investor's Business Daily - Tue Aug 26, 5:45PM CDT
Celgene (CELG) rose 2.4% to 95.66 as an Deutsche Bank analyst said upcoming clinical trial data on a Crohn's disease drug could lift shares. The analyst also touted Gilead Sciences (GILD), which fell 1.1% but is still up 16% in Aug.
Celgene, Gilead Lead Big Biotech Stock Movers
at Investor's Business Daily - Tue Aug 26, 4:55PM CDT
Big-cap biotechs moved in strong volume on the stock market today as Deutsche Bank added several to its short-term buy list, after Citi reported back from visits with medical experts. Celgene (CELG) hit a new high above 95 after Deutsche Bank analyst...
Stocks Rise As Biotechs Lead; Amazon To Buy Twitch
at Investor's Business Daily - Tue Aug 26, 3:58PM CDT
Stocks were moderately higher Monday with biotech stocks leading the way. The Nasdaq and the Dow Jones industrial average rose 0.4% and the S&P 500 gained 0.5%. After the close, Amazon (AMZN) announced it was paying $970 million to buy Twitch, a live...
The Best Hedge Fund You've Never Heard Of and Its Top 5 Stock Picks
at The Street - Tue Aug 26, 1:22PM CDT
It's not the hedge fund mogul you expect.
Stock Market News for August 26, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 9:10AM CDT
The S&P 500 closed at a record high and fellow benchmarks also ended in the green boosted by deal news
Celgene (CELG) Approaches New Upside Target of $94.87
Comtex SmarTrend(R) - Tue Aug 26, 9:01AM CDT
Celgene (NASDAQ:CELG) has opened bullishly above the pivot of $93.13 today and has reached the first level of resistance at $94.13. Investors may be interested in a cross of the next upside pivot targets of $94.87 and $96.61.
3 Reasons Celgene Corporation's Stock Could Fall
Sean Williams, The Motley Fool - Motley Fool - Tue Aug 26, 7:49AM CDT
If you've been a long-term shareholder in Celgene stock you have very little to complain about. The company's core drug, Revlimid, a treatment for blood-borne cancers, has grown into what's expected to be a $5 billion blockbuster this year, and...
'Fast Money' Recap: Next Stop, S&P 2,100?
at The Street - Tue Aug 26, 4:00AM CDT
The trading panel looked at banks and the top buy and sell candidates for right now.